TERINGOVA, Elena, Martin KOZEL, Jiri KNOT, Viktor KOCKA, Klára BENEŠOVÁ and Petr TOUSEK. Relationship between TRAIL and Left Ventricular Ejection Fraction in Patients with ST-Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention. Biomed Research International. New York: Hindawi Publishing Corporation, 2018, vol. 2018, No 3709084, p. 1-8. ISSN 2314-6133. Available from: https://dx.doi.org/10.1155/2018/3709084.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Relationship between TRAIL and Left Ventricular Ejection Fraction in Patients with ST-Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention
Authors TERINGOVA, Elena (203 Czech Republic), Martin KOZEL (203 Czech Republic), Jiri KNOT (203 Czech Republic), Viktor KOCKA (203 Czech Republic), Klára BENEŠOVÁ (203 Czech Republic, belonging to the institution) and Petr TOUSEK (guarantor).
Edition Biomed Research International, New York, Hindawi Publishing Corporation, 2018, 2314-6133.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 20801 Environmental biotechnology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.197
RIV identification code RIV/00216224:14110/18:00104050
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1155/2018/3709084
UT WoS 000439234000001
Keywords in English ST-Elevation Myocardial Infarction Treated
Tags 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 31/10/2019 11:56.
Abstract
Background. Apoptosis plays an important role in the myocardial injury after acute myocardial infarction and in the subsequent development of heart failure. Aim. To clarify serum kinetics of apoptotic markers TRAIL and sFas and their relation to left ventricular ejection fraction (LVEF) in patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). Methods. In 101 patients with STEMI treated with pPCI, levels of TRAIL and sFas were measured in series of serum samples obtained during hospitalization and one month after STEMI. LVEF was assessed at admission and at one month. Major adverse cardiovascular events (MACE, i.e., death, re-MI, and hospitalization for heart failure and stroke) were analysed during a two-year followup. Results. Serum level of TRAIL significantly decreased one day after pPCI (50.5pg/mL) compared to admission (56.7pg/mL), subsequently increased on day 2 after pPCI (58.8pg/mL), and reached its highest level at one month (70.3pg/mL). TRAIL levels on days 1 and 2 showed a significant inverse correlation with troponin and a significant positive correlation with LVEF at baseline. Moreover, TRAIL correlated significantly with LVEF one month after STEMI (day 1: r 0.402, p<0.001; day 2: r 0.542, p<0.001). On the contrary, sFas level was significantly lowest at admission (5073pg/mL), increased one day after pPCI (6370pg/mL), and decreased on day 2 (5548pg/mL). Significantly highest sFas level was marked at one month (7024pg/mL). sFas failed to correlate with LVEF at baseline or at one month. Both TRAIL and sFas showed no ability to predict improvement of LVEF one month after STEMI or a 2-year MACE (represented by 3.29%). Conclusion. In STEMI treated with pPCI, TRAIL reaches its lowest serum concentration after reperfusion. Low TRAIL level is associated with worse LVEF in the acute phase of STEMI as well as one month after STEMI. Higher TRAIL level appears to be beneficial and thus TRAIL seems to represent a protective mediator of post-AMI injury.
PrintDisplayed: 24/7/2024 13:28